Micro/nanomachines: what is needed for them to become a real force in cancer therapy?
Language English Country England, Great Britain Media print
Document type Journal Article, Review
PubMed
30632584
DOI
10.1039/c8nr08022d
Knihovny.cz E-resources
- MeSH
- Biocompatible Materials chemistry MeSH
- Doxorubicin chemistry pharmacology therapeutic use MeSH
- Humans MeSH
- Neoplasms drug therapy pathology MeSH
- Nanostructures chemistry MeSH
- Nanotechnology * MeSH
- Drug Carriers chemistry MeSH
- Antineoplastic Agents chemistry pharmacology therapeutic use MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Biocompatible Materials MeSH
- Doxorubicin MeSH
- Drug Carriers MeSH
- Antineoplastic Agents MeSH
Conventional drug delivery systems face several issues in medical applications, such as cyto/genotoxicity and off-targeting. These issues are particularly significant for cancer therapeutics because many of the currently used systems are toxic in their free form. Self-propelled autonomous micro/nanomachines offer promising alternative drug delivery systems based on high cargo loading, fast autonomous movement, precise targeting and the on-demand release of therapeutics in vivo. With this unique set of properties, it is not surprising that they are receiving considerable research attention. However, much less is reported about the drawbacks that hinder their systemic in vivo application. In this review, a biomedical perspective is used to assess micro/nanomotor-based anticancer drug delivery systems reported to date. Advantages along with present issues are highlighted and recommendations which need to be considered to develop an effective biocompatible micro/nanomotor-based delivery system for cancer therapy are discussed.
References provided by Crossref.org
Magnetically Driven Micro and Nanorobots